PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.02
D/E less than half of AXSM's 0.13. Charlie Munger would verify if this conservative approach provides competitive advantages.
11.50
Higher net debt at 1.1-1.25x AXSM's 9.59. Bruce Berkowitz would look for hidden assets justifying this higher leverage.
No Data
No Data available this quarter, please select a different quarter.
11.71
Current ratio 1.25-1.5x AXSM's 8.30. Mohnish Pabrai would examine if this strength creates buying power advantages.
No Data
No Data available this quarter, please select a different quarter.